NCT07789106Recruiting
A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists
A Randomised, Placebo-Controlled Trial to Evaluate the Effect of Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Who Are Self-Administering GLP-1 Agonists ("Project Zest")
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are: Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment? Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications. Participants will: Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test. Attend a short monthly video call (about 20-30 minutes) with a study dietitian. Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app. Log all exercise sessions in the smartphone app throughout the study. This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 11 Aug 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- StudySetGo
- Diseases
- Obesity
- NCT number
- NCT07789106
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Sept 2026 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
- Prior or current use of statin medication
- Has previously used GLP-1 agonists and/or undergone bariatric surgery
- Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
Other illness
- Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
Other
- Failed screening bloods (any results that is outside of the lab reference range)
- Intention to stop GLP-1 agonist use within 9 months of randomisation
- Pregnancy, breastfeeding or intention to conceive during study
Who the study is looking for
- Age 30-65 years
- Body mass index \>27kg/m2 and \<35 kg/m2
- Currently initiating, or has initiated within the preceding 16 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management.
- Is physically mobile and able to complete at least one sit to stand movements
- Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
- Proficient in English language speaking and reading
- Owns their own digital body weighing scale
- Able and willing to provide full informed consent
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Office 1110 3 Fitzroy Place, 1/1, Sauchiehall Street Coordinator of this site? Confirm its status | Glasgow | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.